UBS AM
APLT

UBS AM’s Applied Therapeutics APLT Stock Holding History

UBS AM’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-119,035
Closed -$102K – 2643
2024
Q4 		$102K Buy
+119,035
New +$746K ﹤0.01% 2640
2022
Q2 		– Sell
-22,695
Closed -$47.9K – 2693
2022
Q1 		$47.9K Hold
22,695
– – ﹤0.01% 2766
2021
Q4 		$203K Hold
22,695
– – ﹤0.01% 2759
2021
Q3 		$377K Hold
22,695
– – ﹤0.01% 2580
2021
Q2 		$472K Buy
+22,695
New +$430K ﹤0.01% 2561
2020
Q3 		– Sell
-6,067
Closed -$219K – 2486
2020
Q2 		$219K Buy
+6,067
New +$254K ﹤0.01% 2363

Other funds holding APLT

VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS AM's APLT Position: Q1 2025 in Review

UBS AM sold out of Applied Therapeutics (APLT) in Q1 2025, closing a stake of 119,035 shares — an estimated $102K sold.

UBS AM first reported a position in APLT in Q2 2020 and held it in 6 quarters. The position peaked at $472K in Q2 2021. 90 funds tracked by Wall St. Rank hold APLT as of Q1 2025.

  • UBS AM reported no remaining Applied Therapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS AM sold 119,035 Applied Therapeutics shares in Q1 2025, an estimated $102K.
  • UBS AM first reported a position in Applied Therapeutics in Q2 2020 and held it in 6 quarters.
  • UBS AM's Applied Therapeutics position peaked at $472K in Q2 2021.
  • 90 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2025.

Based on UBS AM's 13F filing for Q1 2025, filed 19 May 2025.